We are excited to share The PCDH19 Alliance 2015 Annual Report. Our PCDH19 community may be small in number, but look what we accomplished together towards our common goal. Thanks to everyone that joined us in our mission last year. We are off to a great start this year. Now is a great time to get active and and join is in our mission for 2016! Click here to get the report.
Calling all Researchers and Clinicians Interested in PCDH19 Epilepsy! Our 2015 Research Grant Cycle is Open! 2015 Grant Cycle Dates: Submission Deadline: May 1st 2016 Awards Announced: September 1st 2016 Please email Julie Walters with any questions: firstname.lastname@example.org
We are so excited and hopeful to be able to officially share this news: MARINUS PHARMACEUTICALS INITIATES CLINICAL TRIAL WITH GANAXOLONE IN PCDH19 FEMALE PEDIATRIC EPILEPSY RADNOR, PA, February 3, 2015 (Globe Newswire) -- Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative neuropsychiatric therapeutics, announced that it has initiated a Phase 2 clinical trial with ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, in female children with epilepsy caused by a mutation of the protocadherin 19 gene (PCDH19). PCDH19 female pediatric
We are excited to announce that the PCDH19 Epilepsy Registry is now open. Thank you to the teams at Boston Children's Hospital and UCSF for all of their hard work on this Registry thus far and thank you to all the friends of the Alliance, without your generous support this registry would not have been possible. Click here for more information and to enrol.
Just in time for Father's Day. We just received a new shipment of Awareness wristbands that are just waiting to go out there and do some good. They are 4.00 each or 6 for 20.00. To see the PCDH19 wristbands and other awareness clothing and accessories, please check out our PCDH19 Alliance Store